BioAlberta, in partnership with Viresco Solutions, is conducting a survey of Alberta bioindustrial companies to gauge the size and features of the industry, and contribute towards an industry directory.
John Lewis, CEO of BioAlberta member Entos Pharmaceuticals and a lead research scientist at the Alberta Prostate Cancer Initiative, was featured in the Edmonton Journal discussing the potential of ultrasound as a prostate cancer biopsy tool.
OncoQuest is developing an immunotherapeutic compound called Oregovomab to treat ovarian cancer. The drug is currently in a Phase 2B clinical trial at 13 centres in the U.S. and Italy.
SmileSonica proudly announces their orthodontic treatment "Aevo System" has received its medical device license from Health Canada.
Positive interim results reached from the Phase 2b clinical study of its lead product, oregovomab, in patients with advanced epithelial ovarian, adnexal or peritoneal carcinoma.
Quest announce the commercial launch of the Bellus Skin line of premium cosmetic products in Canada on November 17.
The Alberta Export Awards are the province’s most prestigious awards, paying tribute to the success and innovative approaches of Alberta export companies. NanoSpeed is a finalist for the Advanced Technology and Innovation.
Signed Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies.
KMT Hepatech, a long-standing BioAlberta member, wins CV Magazine "Best for Health R&D Business Development - Canada."
OncoQuest Inc, a subsidiary of Edmonton-based Quest PharmaTech Inc., announce positive results from its pre-clinical pharmacology studies using its Anti-MUC1 antibody, MAb AR20.5, against pancreatic cancer in a mouse model.
Singularity University (SU) is offering a spot in their coveted accelerator program to innovative companies in the life sciences.
Ceapro announce the grand opening of its new 30,000-square-foot bioprocessing extraction / manufacturing facility in Edmonton.
Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), today announces the filing on SEDAR of restated financial statements for the year ended January 31, 2016 and for the three-month period ended April 30, 2016 and restated management discussion.
VaxAlta Inc. is pleased to announce a new collaboration with the Faculty of Science at the University of Alberta to advance early stage livestock vaccines research.
A "Point-of-Care Detection for Patients with Acute Myocardial Infarction" CHALLENGE is being launched in close collaboration with DynaLIFE Dx. Don't delay ... apply today!
BioAlberta and the life sciences Industry is thrilled that Minister Deron Bilous will lead the Alberta delegation to BIO 2016. The convention takes place in San Francisco on June 6-9.